                         SEQUENCE LISTING

<110>  Yeda Research and Development Co. Ltd.
 
<120>  NOVEL PEPTIDE COMBINATIONS FOR USE IN THE DIAGNOSIS OF 
       SCHIZOPHRENIA

<130>  2410993

<150>  US 62/192,206
<151>  2015-07-14

<160>  30    

<170>  PatentIn version 3.5

<210>  1
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  1

Leu Leu Val Val Gly 
1               5   


<210>  2
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  2

Leu Leu Val Gly Val 
1               5   


<210>  3
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  3

Leu Leu Gly Val Val 
1               5   


<210>  4
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  4

Leu Val Leu Val Gly 
1               5   


<210>  5
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  5

Leu Val Leu Gly Val 
1               5   


<210>  6
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  6

Leu Gly Leu Val Val 
1               5   


<210>  7
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  7

Leu Val Val Leu Gly 
1               5   


<210>  8
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  8

Leu Val Gly Leu Val 
1               5   


<210>  9
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  9

Leu Gly Val Leu Val 
1               5   


<210>  10
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  10

Leu Val Val Gly Leu 
1               5   


<210>  11
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  11

Leu Val Gly Val Leu 
1               5   


<210>  12
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  12

Leu Gly Val Val Leu 
1               5   


<210>  13
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  13

Val Leu Leu Val Gly 
1               5   


<210>  14
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  14

Val Leu Leu Gly Val 
1               5   


<210>  15
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  15

Gly Leu Leu Val Val 
1               5   


<210>  16
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  16

Val Leu Val Leu Gly 
1               5   


<210>  17
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  17

Val Leu Gly Leu Val 
1               5   


<210>  18
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  18

Gly Leu Val Leu Val 
1               5   


<210>  19
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  19

Val Leu Val Gly Leu 
1               5   


<210>  20
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  20

Val Leu Gly Val Leu 
1               5   


<210>  21
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  21

Gly Leu Val Val Leu 
1               5   


<210>  22
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  22

Val Val Leu Leu Gly 
1               5   


<210>  23
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  23

Val Gly Leu Leu Val 
1               5   


<210>  24
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  24

Gly Val Leu Leu Val 
1               5   


<210>  25
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  25

Val Val Leu Gly Leu 
1               5   


<210>  26
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  26

Val Gly Leu Val Leu 
1               5   


<210>  27
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  27

Gly Val Leu Val Leu 
1               5   


<210>  28
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  28

Val Val Gly Leu Leu 
1               5   


<210>  29
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  29

Val Gly Val Leu Leu 
1               5   


<210>  30
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pentapeptide component

<400>  30

Gly Val Val Leu Leu 
1               5   


